ibtrozi
Generic: taletrectinib
ibtrozi: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Nuvation Bio Inc. (NUVB) | Approved |
FDA Decisions
FDA_MeetingFDA accepted and granted priority review of the New Drug Application for taletrectinib for treatment of advanced ROS1-positive non-small cell lung cancer.(NUVB)
Frequently asked questions
Who is developing ibtrozi?
ibtrozi is being developed by Nuvation Bio Inc..
What is ibtrozi's latest FDA decision?
The most recent tracked FDA decision for ibtrozi is FDA_Meeting for FDA accepted and granted priority review of the New Drug Application for taletrectinib for treatment of advanced ROS1-positive non-small cell lung cancer..
Get deeper analysis on ibtrozi
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis